Crescendo Bioscience, a subsidiary of Myriad Genetics, specializes in molecular diagnostics with a focus on identifying hereditary cancer risks and optimizing treatment plans through genetic insights. The company serves healthcare providers and patients, primarily in the oncology and pharmacogenomics sectors. Operating within the precision medicine market, Crescendo Bioscience leverages advanced sequencing and analysis techniques to offer multi-gene panel tests, such as the Myriad myRisk Hereditary Cancer test, which assesses the risk for eight different hereditary cancers. Their GeneSight test is another key product, providing pharmacogenomic insights to help healthcare providers tailor antidepressant treatments for better patient outcomes. The business model revolves around selling these diagnostic tests to healthcare providers, who then use the results to inform patient care. Revenue is generated through test sales and associated services. Crescendo Bioscience's commitment to innovation and patient care drives its operations, aiming to answer the most pressing questions about disease and improve patient outcomes.

Keywords: molecular diagnostics, hereditary cancer, genetic insights, precision medicine, oncology, pharmacogenomics, sequencing, multi-gene panel, patient outcomes, healthcare providers.